Peptide Therapeutics Market - By Type (Branded, Generic), By Application (Metabolic, Cancer, Cardiovascular, Gastrointestinal), By Route of Administration (Parenteral, Oral), By Distribution Channel (Hospital, Retail)- Global Forecast 2023 to 2032

Peptide Therapeutics Market - By Type (Branded, Generic), By Application (Metabolic, Cancer, Cardiovascular, Gastrointestinal), By Route of Administration (Parenteral, Oral), By Distribution Channel (Hospital, Retail)- Global Forecast 2023 to 2032

Global Peptide Therapeutics Market will exhibit exponential growth over 2023- 2032.

Increasing demand for personalized and targeted treatment options pushed by the growing burden of chronic diseases such as diabetes, cancer, and cardiovascular disorders will stimulate industry revenue streams over the next ten years. According to WHO, diabetes affects around 422 million people worldwide and claims the lives of 1.5 million people each year.

Peptide therapeutics offer advantages like high specificity, low toxicity, and excellent biocompatibility, making them an attractive choice for drug development. Advancements in peptide synthesis technologies and drug delivery systems have improved the stability, bioavailability, and half-life of peptide drugs, further propelling their adoption. Moreover, ongoing R&D activities, in line with increasing collaborations between academic institutions and pharmaceutical companies, will fuel the discovery of novel peptide-based therapies, driving market growth.

The overall peptide therapeutics market share is categorized based on type, application, route of administration, distribution channel, and region.

Regarding the type, the generic peptide therapeutics industry will register significant gains through 2032. The expiration of patents for original peptide drugs has opened the market for generic versions, offering cost-effective alternatives. The increasing burden of chronic diseases has created a need for affordable treatment options, further stimulating the demand for generic peptide therapeutics. Besides, regulatory initiatives promoting the use of generic drugs have encouraged their adoption in healthcare systems worldwide, which will help augment segment gains over the coming years.

With respect to application, the peptide therapeutics market size from the cancer segment will grow substantially over 2023-2032. The demand for peptide therapeutics in cancer applications is increasing due to their potential for targeted and personalized treatment. Peptides can specifically target cancer cells while sparing healthy cells, reducing side effects. Additionally, peptide-based immunotherapies, such as immune checkpoint inhibitors, have shown promising results in boosting the body's immune response against cancer cells.

Based on the route of administration, the oral segment could amass a notable share of the peptide therapeutics industry revenue by 2032. Oral delivery is non-invasive and more convenient for patients, improving compliance and treatment adherence. Advances in formulation technologies, such as the use of peptide stabilizers and enzyme inhibitors, have improved the oral bioavailability and stability of peptide drugs. This apart, oral delivery offers potential cost savings compared to other routes, such as injections or infusions, further contributing to segment gains.

Regionally, the Asia Pacific peptide therapeutics market will exhibit an appreciable growth rate between 2023 and 2032. The increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders, has created a significant need for effective treatment options. Rising healthcare expenditures, expanding middle-class population, and improving healthcare infrastructure have further contributed to the increasing demand. Besides, advancements in R&D capabilities in countries like China, Japan, and South Korea have fostered innovation, and the development of peptide-based therapies will drive market growth in the region.